Drugs / Yttrium-90 (Y-90)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00846131 | Feb 2009 → Jul 2015 | hepatocellular carcinoma | Northwestern University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yttrium-90 (Y-90) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00846131 ↗ |
| Known as | Therasphere | “All subjects enrolled in this study will be treated with the use of Therasphere, Y-90, which is composed of nonbiodegradable glass microspheres coated with the radioactive...” NCT00846131 ↗ |
| Modality | Other / unclassified | “nonbiodegradable glass microspheres coated with the radioactive compound Y-90” NCT00846131 ↗ |
| Route | Other | “injected into the hepatic artery” NCT00846131 ↗ |